Search

Your search keyword '"Vanderstichele, Hugo"' showing total 783 results
Start Over Author "Vanderstichele, Hugo"
783 results on '"Vanderstichele, Hugo"'

1. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Author

Schindler, Suzanne E., Galasko, Douglas, Pereira, Ana C., Rabinovici, Gil D., Salloway, Stephen, Suárez-Calvet, Marc, Khachaturian, Ara S., Mielke, Michelle M., Udeh-Momoh, Chi, Weiss, Joan, Batrla, Richard, Bozeat, Sasha, Dwyer, John R., Holzapfel, Drew, Jones, Daryl Rhys, Murray, James F., Partrick, Katherine A., Scholler, Emily, Vradenburg, George, Young, Dylan, Algeciras-Schimnich, Alicia, Aubrecht, Jiri, Braunstein, Joel B., Hendrix, James, Hu, Yan Helen, Mattke, Soeren, Monane, Mark, Reilly, David, Somers, Elizabeth, Teunissen, Charlotte E., Shobin, Eli, Vanderstichele, Hugo, Weiner, Michael W., Wilson, David, and Hansson, Oskar

Published
2024
Full Text
View/download PDF

2. Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults

Author

Yuan, Jun, Pedrini, Steve, Thota, Rohith, Doecke, James, Chatterjee, Pratishtha, Sohrabi, Hamid R., Teunissen, Charlotte E., Verberk, Inge M. W., Stoops, Erik, Vanderstichele, Hugo, Meloni, Bruno P., Mitchell, Christopher, Rainey-Smith, Stephanie, Goozee, Kathryn, Tai, Andrew Chi Pang, Ashton, Nicholas, Zetterberg, Henrik, Blennow, Kaj, Gao, Junjie, Liu, Delin, Mastaglia, Frank, Inderjeeth, Charles, Zheng, Minghao, and Martins, Ralph N.

Published
2023
Full Text
View/download PDF

3. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Author

O'Bryant, Sid E, Mielke, Michelle M, Rissman, Robert A, Lista, Simone, Vanderstichele, Hugo, Zetterberg, Henrik, Lewczuk, Piotr, Posner, Holly, Hall, James, Johnson, Leigh, Fong, Yiu‐Lian, Luthman, Johan, Jeromin, Andreas, Batrla‐Utermann, Richard, Villarreal, Alcibiades, Britton, Gabrielle, Snyder, Peter J, Henriksen, Kim, Grammas, Paula, Gupta, Veer, Martins, Ralph, Hampel, Harald, and Area, Biofluid Based Biomarker Professional Interest

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Dementia, Aging, Neurodegenerative, Brain Disorders, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Clinical Research, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Neurological, Alzheimer Disease, Biomarkers, Cooperative Behavior, Female, Humans, Male, Public-Private Sector Partnerships, Reproducibility of Results, Alzheimer's disease, Biomarker, Blood, Diagnosis, Cerebrospinal fluid, Imaging, Context of use, Biofluid Based Biomarker Professional Interest Area, Geriatrics, Clinical sciences, Biological psychology
Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Published
2017

6. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects

Author

Toledo, Jon B, Zetterberg, Henrik, van Harten, Argonde C, Glodzik, Lidia, Martinez-Lage, Pablo, Bocchio-Chiavetto, Luisella, Rami, Lorena, Hansson, Oskar, Sperling, Reisa, Engelborghs, Sebastiaan, Osorio, Ricardo S, Vanderstichele, Hugo, Vandijck, Manu, Hampel, Harald, Teipl, Stefan, Moghekar, Abhay, Albert, Marilyn, Hu, William T, Argilés, Jose A Monge, Gorostidi, Ana, Teunissen, Charlotte E, De Deyn, Peter P, Hyman, Bradley T, Molinuevo, Jose L, Frisoni, Giovanni B, Linazasoro, Gurutz, de Leon, Mony J, van der Flier, Wiesje M, Scheltens, Philip, Blennow, Kaj, Shaw, Leslie M, and Trojanowski, John Q

Subjects
Biomedical and Clinical Sciences, Health Sciences, Psychology, Brain Disorders, Clinical Research, Acquired Cognitive Impairment, Aging, Dementia, Neurodegenerative, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Neurosciences, 2.1 Biological and endogenous factors, Aetiology, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Neurological, Adult, Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Peptides, Analysis of Variance, Apolipoproteins E, Cognition, Cohort Studies, Female, Humans, Male, Middle Aged, Neurodegenerative Diseases, Neuropsychological Tests, Peptide Fragments, Severity of Illness Index, tau Proteins, Alzheimer's disease, dementia, biomarkers, cognitive ageing, imaging, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s disease, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery, Biomedical and clinical sciences, Health sciences
Abstract

In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.

Published
2015

7. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Author

Kang, Ju‐Hee, Korecka, Magdalena, Figurski, Michal J, Toledo, Jon B, Blennow, Kaj, Zetterberg, Henrik, Waligorska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly, Dean, Robert A, Vanderstichele, Hugo, Petersen, Ronald C, Aisen, Paul S, Saykin, Andrew J, Weiner, Michael W, Trojanowski, John Q, Shaw, Leslie M, and Initiative, Alzheimer's Disease Neuroimaging

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Brain Disorders, Aging, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Alzheimer's Disease, Prevention, Acquired Cognitive Impairment, Neurodegenerative, Dementia, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Neurological, Alzheimer Disease, Amyloid beta-Peptides, Databases, Bibliographic, Humans, Peptide Fragments, tau Proteins, Alzheimer's disease, Mild cognitive impairment, Cerebrospinal fluid, Plasma, Biomarkers, Immunoassay, ADNI, Disease-modifying therapy, A beta(1-42), Tau, Alzheimer's Disease Neuroimaging Initiative, Aβ(1–42), Geriatrics, Clinical sciences, Biological psychology
Abstract

IntroductionWe describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.MethodsReview publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data.ResultsCSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies.DiscussionFurther studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.

Published
2015

18. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Author

Verberk, Inge M. W., Thijssen, Elisabeth, Koelewijn, Jannet, Mauroo, Kimberley, Vanbrabant, Jeroen, de Wilde, Arno, Zwan, Marissa D., Verfaillie, Sander C. J., Ossenkoppele, Rik, Barkhof, Frederik, van Berckel, Bart N. M., Scheltens, Philip, van der Flier, Wiesje M., Stoops, Erik, Vanderstichele, Hugo M., and Teunissen, Charlotte E.

Published
2020
Full Text
View/download PDF

22. Presenilin 2 Deficiency Causes a Mild Pulmonary Phenotype and no Changes in Amyloid Precursor Protein Processing but Enhances the Embryonic Lethal Phenotype of Presenilin 1 Deficiency

Author

Herreman, An, Hartmann, Dieter, Annaert, Wim, Saftig, Paul, Craessaerts, Katleen, Serneels, Lutgarde, Umans, Lieve, Schrijvers, Vincent, Checler, Frederic, Vanderstichele, Hugo, Baekelandt, Veerle, Dressel, Ralf, Cupers, Philippe, Huylebroeck, Danny, Zwijsen, An, Van Leuven, Freb, and De Strooper, Bart

Published
1999

26. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Author

Rembach, Alan, Faux, Noel G., Watt, Andrew D., Pertile, Kelly K., Rumble, Rebecca L., Trounson, Brett O., Fowler, Christopher J., Roberts, Blaine R., Perez, Keyla A., Li, Qiao-Xin, Laws, Simon M., Taddei, Kevin, Rainey-Smith, Stephanie, Robertson, Joanne S., Vandijck, Manu, Vanderstichele, Hugo, Barnham, Kevin J., Ellis, Kathryn A., Szoeke, Cassandra, Macaulay, Lance, Rowe, Christopher C., Villemagne, Victor L., Ames, David, Martins, Ralph N., Bush, Ashley I., and Masters, Colin L.

Published
2014
Full Text
View/download PDF

29. CSF biomarker variability in the Alzheimer's Association quality control program

Author

Rojo, Aladro José A., Albert, Marilyn, Alcolea, Daniel, Andreasson, Ulf, Antonell, Anna, Arai, Hiroyuki, Archetti, Silvana, Arkblad, Eva, Baldeiras, Inês, Bartos, Ales, Batish, Dev, Bedel, Aurélie, Bentue-Ferrer, Daniele, Berisha, Flora, Bernardini, Sergio, Blankenstein, Marinus, Blennow, Kaj, Bousiges, Olivier, Camuso, Michael C., Carrillo, Maria, Casoli, Tiziana, Cavallaro, Sebastiano, Chalbot, Sonia, Collins, Steven, Cruz e Silva, Odete, Cutler, Neal, Cuvelier, Isabelle, Delaroche, Odile, Dufour-Rainfray, Diane, Dyer, Roy, Engelborghs, Sebastiaan, Fagan, Anne M., Fogli, Anne, Forlenza, Orestes V., Fox, Nick, Frisoni, Giovanni, Galimberti, Daniela, Galloni, Elisabetta, Gritti, Silvana, Gylys, Karen H., Hampel, Harald, Haustein, Sabine, Heath, Theresa, Heegaard, Niels H.H., Heneka, Michael T., Herukka, Sanna-Kaisa, Holtzman, David, Hsiung, Ging-Yuek Robin, Humpel, Christian, Hyman, Bradley, Iwatsubo, Takeshi, Iqbal, Khalid, Jardel, Claude, Jucker, Mathias, Kapaki, Elisabeth, Käser, Stephan A., Kidd, Daniel, Klivenyi, Peter, Kuwano, Ryozo, Lachno, D. Richard, Lamari, Foudil, Laplanche, Jean-Louis, Laser, Jordan, Lehmann, Sylvian, Lewczuk, Piotr, Li, Qiao-Xin, Lleó, Alberto, Maetzler, Walter, Malaplate-Armand, Catherine, Martin, Ralph, Martone, Robert L., Masters, Colin, Mattsson, Niklas, Mercken, Marc, Molinuevo, José Luis, Montine, Tom, Nowatzke, William, Otto, Markus, Parchi, Piero, Parent, Xavier, Parnetti, Lucilla, Persson, Staffan, Petersen, Ronald, Poesen, Koen, Quadrio, Isabelle, Quillard, Muriel, Regeniter, Axel, Rello, Vara Luis, Rissman, Robert, Rohan, Zdenek, Rosenmann, Hanna, Sancesario, Giuseppe, Schröder, Johannes, Shaw, Leslie M., Sisowath, Christin, Skinningsrud, Anders, Soares, Holly, Soininen, Hilkka, Søndersø, Knudsen Cindy, Spreer, Annette, Suardi, Silvia, Teunissen, Charlotte, Trojanowski, John Q., Umek, Robert, Van Broeck, Bianca, Vandenberghe, Rik, Vanderstichele, Hugo, Vandijck, Manu, Vecsei, Laszlo, Verbeek, Marcel, Vostiar, Igor, Windisch, Manfred, Zetterberg, Henrik, Carrillo, Maria C., Robin Hsiung, Ging-Yuek, Molinuevo, José L., Teunissen, Charlotte E., and Verbeek, Marcel M.

Published
2013
Full Text
View/download PDF

32. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

Author

Mattsson, Niklas, Andreasson, Ulf, Persson, Staffan, Arai, Hiroyuki, Batish, Sat Dev, Bernardini, Sergio, Bocchio-Chiavetto, Luisella, Blankenstein, Marinus A., Carrillo, Maria C., Chalbot, Sonia, Coart, Els, Chiasserini, Davide, Cutler, Neal, Dahlfors, Gunilla, Duller, Stefan, Fagan, Anne M., Forlenza, Orestes, Frisoni, Giovanni B., Galasko, Douglas, Galimberti, Daniela, Hampel, Harald, Handberg, Aase, Heneka, Michael T., Herskovits, Adrianna Z., Herukka, Sanna-Kaisa, Holtzman, David M., Humpel, Christian, Hyman, Bradley T., Iqbal, Khalid, Jucker, Mathias, Kaeser, Stephan A., Kaiser, Elmar, Kapaki, Elisabeth, Kidd, Daniel, Klivenyi, Peter, Knudsen, Cindy S., Kummer, Markus P., Lui, James, Lladó, Albert, Lewczuk, Piotr, Li, Qiao-Xin, Martins, Ralph, Masters, Colin, McAuliffe, John, Mercken, Marc, Moghekar, Abhay, Molinuevo, José Luis, Montine, Thomas J., Nowatzke, William, O’Brien, Richard, Otto, Markus, Paraskevas, George P., Parnetti, Lucilla, Petersen, Ronald C., Prvulovic, David, de Reus, Herman P.M., Rissman, Robert A., Scarpini, Elio, Stefani, Alessandro, Soininen, Hilkka, Schröder, Johannes, Shaw, Leslie M., Skinningsrud, Anders, Skrogstad, Brith, Spreer, Annette, Talib, Leda, Teunissen, Charlotte, Trojanowski, John Q., Tumani, Hayrettin, Umek, Robert M., Van Broeck, Bianca, Vanderstichele, Hugo, Vecsei, Laszlo, Verbeek, Marcel M., Windisch, Manfred, Zhang, Jing, Zetterberg, Henrik, and Blennow, Kaj

Published
2011
Full Text
View/download PDF

33. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Author

Bjerke, Maria, Andreasson, Ulf, Kuhlmann, Julia, Portelius, Erik, Pannee, Josef, Lewczuk, Piotr, Umek, Robert M., Vanmechelen, Eugeen, Vanderstichele, Hugo, Stoops, Erik, Lewis, Jennifer, Vandijck, Manu, Kostanjevecki, Vesna, Jeromin, Andreas, Salamone, Salvatore J., Schmidt, Oliver, Matzen, Anja, Madin, Kairat, Eichenlaub, Udo, Bittner, Tobias, Shaw, Leslie M., Zegers, Ingrid, Zetterberg, Henrik, and Blennow, Kaj

Published
2016
Full Text
View/download PDF

39. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Author

Lleó, Alberto, Cavedo, Enrica, Parnetti, Lucilla, Vanderstichele, Hugo, Herukka, Sanna Kaisa, Andreasen, Niels, Ghidoni, Roberta, Lewczuk, Piotr, Jeromin, Andreas, Winblad, Bengt, Tsolaki, Magda, Mroczko, Barbara, Visser, Pieter Jelle, Santana, Isabel, Svenningsson, Per, Blennow, Kaj, Aarsland, Dag, Molinuevo, José Luis, Zetterberg, Henrik, and Mollenhauer, Brit

Published
2015
Full Text
View/download PDF

44. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study

Author

Lewczuk, Piotr, Kornhuber, Johannes, Vanderstichele, Hugo, Vanmechelen, Eugeen, Esselmann, Hermann, Bibl, Mirko, Wolf, Stefanie, Otto, Markus, Reulbach, Udo, Kölsch, Heike, Jessen, Frank, Schröder, Johannes, Schönknecht, Peter, Hampel, Harald, Peters, Oliver, Weimer, Erik, Perneczky, Robert, Jahn, Holger, Luckhaus, Christian, Lamla, Ulrich, Supprian, Tillmann, Maler, Juan Manuel, and Wiltfang, Jens

Published
2008
Full Text
View/download PDF

46. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Author

Hansson, Oskar, primary, Batrla, Richard, additional, Brix, Britta, additional, Carrillo, Maria C., additional, Corradini, Veronika, additional, Edelmayer, Rebecca M., additional, Esquivel, Rianne N., additional, Hall, Christina, additional, Lawson, John, additional, Bastard, Nathalie Le, additional, Molinuevo, José Luis, additional, Nisenbaum, Laura K., additional, Rutz, Sandra, additional, Salamone, Salvatore J., additional, Teunissen, Charlotte E., additional, Traynham, Christopher, additional, Umek, Robert M., additional, Vanderstichele, Hugo, additional, Vandijck, Manu, additional, Wahl, Simone, additional, Weber, Christopher J., additional, Zetterberg, Henrik, additional, and Blennow, Kaj, additional

Published
2021
Full Text
View/download PDF

47. Onset of Preclinical Alzheimer Disease in Monozygotic Twins

Author

Konijnenberg, Elles, primary, Tomassen, Jori, additional, Braber, Anouk, additional, Kate, Mara, additional, Yaqub, Maqsood, additional, Mulder, Sandra D., additional, Nivard, Michel G., additional, Vanderstichele, Hugo, additional, Lammertsma, Adriaan A., additional, Teunissen, Charlotte E., additional, Berckel, Bart N. M., additional, Boomsma, Dorret I., additional, Scheltens, Philip, additional, Tijms, Betty M., additional, and Visser, Pieter Jelle, additional

Published
2021
Full Text
View/download PDF

48. Effect of the micro-environment on alpha-synuclein conversion and implication in seeded conversion assays

Author

Candelise, Niccolo, Schmitz, Matthias, Thüne, Katrin, Cramm, Maria, Rabano, Alberto, Zafar, Saima, Stoops, Erik, Vanderstichele, Hugo, Villar Piqué, Anna, Llorens Torres, Franc, and Zerr, Inga

Subjects
Alpha-synuclein, nervous system, animal diseases, Malaltia de Parkinson, Parkinson's disease, mental disorders, Demència amb cossos de Lewy, Alfa-sinucleïna, Lewy body dementia, nervous system diseases
Abstract

Background: α-Synuclein is a small soluble protein, whose physiological function in the healthy brain is poorly understood. Intracellular inclusions of α-synuclein, referred to as Lewy bodies (LBs), are pathological hallmarks of α- synucleinopathies, such as Parkinson’s disease (PD) or dementia with Lewy bodies (DLB). Main body: Understanding of the molecular basis as well as the factors or conditions promoting α-synuclein misfolding and aggregation is an important step towards the comprehension of pathological mechanism of α- synucleinopathies and for the development of efficient therapeutic strategies. Based on the conversion and aggregation mechanism of α-synuclein, novel diagnostic tests, such as protein misfolding seeded conversion assays, e.g. the real-time quaking-induced conversion (RT-QuIC), had been developed. In diagnostics, α-synuclein RT-QuIC exhibits a specificity between 82 and 100% while the sensitivity varies between 70 and 100% among different laboratories. In addition, the α-synuclein RT-QuIC can be used to study the α-synuclein-seeding-characteristics of different α-synucleinopathies and to differentiate between DLB and PD. Conclusion: The variable diagnostic accuracy of current α-synuclein RT-QuIC occurs due to different protocols, cohorts and material etc.. An impact of micro-environmental factors on the α-synuclein aggregation and conversion process and the occurrence and detection of differential misfolded α-synuclein types or strains might underpin the clinical heterogeneity of α-synucleinopathies.

Published
2020

49. Additional file 1 of CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease

Author

Mouton-Liger, François, Dumurgier, Julien, Cognat, Emmanuel, Hourregue, Claire, Zetterberg, Henrik, Vanderstichele, Hugo, Eugeen Vanmechelen, Bouaziz-Amar, Elodie, Blennow, Kaj, Hugon, Jacques, and Paquet, Claire

Subjects
mental disorders
Abstract

Additional file 1: Supplementary Table 1. Spearman correlation coefficients between CSF NRG1 and characteristics in AD + MCI-AD patients.

Published
2020
Full Text
View/download PDF

50. Additional file 1 of Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

Author

Meyer, Steffi De, Schaeverbeke, Jolien M., Verberk, Inge M. W., Gille, Benjamin, Schaepdryver, Maxim De, Luckett, Emma S., Gabel, Silvy, Bruffaerts, Rose, Mauroo, Kimberley, Thijssen, Elisabeth H., Stoops, Erik, Vanderstichele, Hugo M., Teunissen, Charlotte E., Vandenberghe, Rik, and Poesen, Koen

Subjects
mental disorders
Abstract

Additional file 1: Appendix 1. Conversion of [18F]flutemetamol and [18F]florbetaben SUVR to the Centiloid scale. Supplementary Table 1. Plasma amyloid and tau performance (AUC) differences between platforms and subgroups for detecting amyloid-PET positivity. Supplementary Table 2. Performance of adjusted biomarker models relative to a basic demographic model and unadjusted biomarker models Supplementary Table 3. Sensitivities, specificities, PPVs and NPVs of logistic regression models corrected for age and APOE-ε4 genotype. Supplementary Figure 1. Comparison of ELISA and SIMOA measurements of plasma Aβ1-42/Aβ1-40 and Aβ1-42/t-tau. Supplementary Figure 2. ROC curves of plasma amyloid and tau with amyloid-PET as the standard-of-truth. Supplementary Figure 3. Correlations of ELISA and SIMOA plasma amyloid and tau levels with Centiloids and CSF Aβ1-42/t-tau.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results